 |
PDBsum entry 3pur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oxidoreductase/oxidoreductase inhibitor
|
PDB id
|
|
|
|
3pur
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
PDB id:
|
|
|
|
| Name: |
|
Oxidoreductase/oxidoreductase inhibitor
|
|
|
Title:
|
|
Cekdm7a from c.Elegans, complex with d-2-hg
|
|
Structure:
|
|
Lysine-specific demethylase 7 homolog. Chain: a, c. Fragment: phd domain. Synonym: lysine demethylase, cekdm7a, phd finger protein 8 homolog, phf8 homolog. Engineered: yes
|
|
Source:
|
|
Caenorhabditis elegans. Nematode. Organism_taxid: 6239. Gene: f29b9.2. Expressed in: escherichia coli. Expression_system_taxid: 562.
|
|
Resolution:
|
|
|
2.10Å
|
R-factor:
|
0.216
|
R-free:
|
0.251
|
|
|
Authors:
|
|
Y.Yang,P.Wang,W.Xu,Y.Xu
|
|
Key ref:
|
|
W.Xu
et al.
(2011).
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Cancer Cell,
19,
17-30.
PubMed id:
|
|
|
Date:
|
|
|
06-Dec-10
|
Release date:
|
26-Jan-11
|
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
|
Headers
|
|
|
|
References
|
|
|
|
|
|
|
|
Q9GYI0
(KDM7_CAEEL) -
Lysine-specific demethylase 7 homolog from Caenorhabditis elegans
|
|
|
|
Seq:
Struc:
|
|
|
|
910 a.a.
483 a.a.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Key: |
 |
PfamA domain |
|
|
 |
Secondary structure |
|
 |
CATH domain |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
|
Cancer Cell
19:17-30
(2011)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
|
|
W.Xu,
H.Yang,
Y.Liu,
Y.Yang,
P.Wang,
S.H.Kim,
S.Ito,
C.Yang,
P.Wang,
M.T.Xiao,
L.X.Liu,
W.Q.Jiang,
J.Liu,
J.Y.Zhang,
B.Wang,
S.Frye,
Y.Zhang,
Y.H.Xu,
Q.Y.Lei,
K.L.Guan,
S.M.Zhao,
Y.Xiong.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
A.H.Shih,
O.Abdel-Wahab,
J.P.Patel,
and
R.L.Levine
(2012).
The role of mutations in epigenetic regulators in myeloid malignancies.
|
| |
Nat Rev Cancer,
12,
599-612.
|
|
|
|
|
|
|
A.Schulze,
and
A.L.Harris
(2012).
How cancer metabolism is tuned for proliferation and vulnerable to disruption.
|
| |
Nature,
491,
364-373.
|
|
|
|
|
|
|
C.Lu,
P.S.Ward,
G.S.Kapoor,
D.Rohle,
S.Turcan,
O.Abdel-Wahab,
C.R.Edwards,
R.Khanin,
M.E.Figueroa,
A.Melnick,
K.E.Wellen,
D.M.O'Rourke,
S.L.Berger,
T.A.Chan,
R.L.Levine,
I.K.Mellinghoff,
and
C.B.Thompson
(2012).
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
|
| |
Nature,
483,
474-478.
|
|
|
|
|
|
|
M.Sasaki,
C.B.Knobbe,
J.C.Munger,
E.F.Lind,
D.Brenner,
A.Brüstle,
I.S.Harris,
R.Holmes,
A.Wakeham,
J.Haight,
A.You-Ten,
W.Y.Li,
S.Schalm,
S.M.Su,
C.Virtanen,
G.Reifenberger,
P.S.Ohashi,
D.L.Barber,
M.E.Figueroa,
A.Melnick,
J.C.Zúñiga-Pflücker,
and
T.W.Mak
(2012).
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
|
| |
Nature,
488,
656-659.
|
|
|
|
|
|
|
P.Koivunen,
S.Lee,
C.G.Duncan,
G.Lopez,
G.Lu,
S.Ramkissoon,
J.A.Losman,
P.Joensuu,
U.Bergmann,
S.Gross,
J.Travins,
S.Weiss,
R.Looper,
K.L.Ligon,
R.G.Verhaak,
H.Yan,
and
W.G.Kaelin
(2012).
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
|
| |
Nature,
483,
484-488.
|
|
|
|
|
|
|
S.Turcan,
D.Rohle,
A.Goenka,
L.A.Walsh,
F.Fang,
E.Yilmaz,
C.Campos,
A.W.Fabius,
C.Lu,
P.S.Ward,
C.B.Thompson,
A.Kaufman,
O.Guryanova,
R.Levine,
A.Heguy,
A.Viale,
L.G.Morris,
J.T.Huse,
I.K.Mellinghoff,
and
T.A.Chan
(2012).
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
|
| |
Nature,
483,
479-483.
|
|
|
|
|
|
|
M.G.Vander Heiden
(2011).
Targeting cancer metabolism: a therapeutic window opens.
|
| |
Nat Rev Drug Discov,
10,
671-684.
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
|
Links
